Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer

PURPOSE: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA-approved for HER2-overexpressing/amplified (HER2(+)) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of downstream signaling in HER2(+) cancers in vitro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Zhao, Ming, Scott, Stephen, Evans, Kurt W., Yuca, Erkan, Saridogan, Turcin, Zhang, Xiaofeng, Wang, Heping, Korkut, Anil, Pico, Christian X. Cruz, Demirhan, Mehmet, Kirby, Bryce, Kopetz, Scott, Diala, Irmina, Lalani, Alshad S., Piha-Paul, Sarina, Meric-Bernstam, Funda
Format: Artigo
Jezik:Inglês
Izdano: 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8075007/
https://ncbi.nlm.nih.gov/pubmed/33414137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3017
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items